近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Xu L, Xu S, Wang H, Zhang J, Chen Z, Pan L, Wang J, Wei X, Xie H, Zhou L, Zheng S, Xu X. Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting. ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3229-3240.
Ding SM, Lu AL, Zhang W, Zhou L, Xie HY, Zheng SS, Li QY. The role of cancer-associated fibroblast MRC-5 in pancreatic cancer. J Cancer. 2018 Jan 5;9(3):614-628.
Sun JH, Zhang YL, Nie CH, Li J, Zhou TY, Zhou GH, Zhu TY, Chen LM, Wang WL, Zheng SS. Effects of liver cirrhosis on portal vein embolization prior to right hepatectomy in patients with primary liver cancer. Oncol Lett. 2018 Feb;15(2):1411-1416.
Li JH, Jia JJ, Shen W, Chen SS, Jiang L, Xie HY, Zhou L, Zheng SS. Optimized postconditioning algorithm protects liver graft after liver transplantation in rats. Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):32-38.
Huang Y, Kong Y, Zhang L, He T, Zhou X, Yan Y, Zhang L, Zhou D, Lu S, Zhou J,Zhou L, Xie H, Zheng S, Wang W. High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma. Biomed Res Int. 2018 Feb 4;2018:2352139.
Liu Z, Li J, Chen J, Shan Q, Dai H, Xie H, Zhou L, Xu X, Zheng S. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC Cancer. 2018 Feb 20;18(1):200.
Zhou B, Zhan C, Ding Y, Yan S, Zheng S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. Onco Targets Ther. 2018 Feb 23;11:975-982.
Lu D, Wang W, Liu J, Qi L, Zhuang R, Zhuo J, Zhang X, Xu X, Zheng S. Peroxiredoxins in inflammatory liver diseases and ischemic/reperfusion injury in liver transplantation. Food Chem Toxicol. 2018 Mar;113:83-89.
Chen Y, Wei H, Liu Y, Zheng S. Promotional effect of microRNA-194 on breast cancer cells via targeting F-box/WD repeat-containing protein 7. Oncol Lett. 2018 Apr;15(4):4439-4444.
Du F, Yu Y, Zhou Z, Wang L, Zheng S. Early treatment using fractional CO2 laser before skin suture during scar revision surgery in Asians. J Cosmet Laser Ther. 2018 Apr;20(2):102-105.
Yang B, Tong R, Liu H, Wu J, Chen D, Xue Z, Ding C, Zhou L, Xie H, Wu J, Zheng S. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma. Int J Oncol. 2018 Apr;52(4):1235-1245.
Qiao Y, Li T, Zheng S, Wang H. The Hippo pathway as a drug target in gastric cancer. Cancer Lett. 2018 Apr 28;420:14-25.
Shi SH, Feng XN, Wang ZY, Sun K, Xu JF, Kong HS, Zheng SS. Pyogenic liver abscess related to intrahepatic bile duct stones: Difficulties in infectious control and diagnosis of concomitant cholangiocarcinoma. J Gastroenterol Hepatol. 2018 May;33(5):1092-1099.
Shao Y, Yan S, Zhang QY, Shen Y, Zhang M, Wang WL, Zheng SS. Autologous falciform ligament graft as A substitute for mesentericoportal vein reconstruction in pancreaticoduodenectomy. Int J Surg. 2018 May;53:159-162.
Hu X, He B, Zhou L, Zheng S. Elevated TEAD1 Expression is not an Independent Prognosis Factor of Hepatocellular Carcinoma. Clin Lab. 2018 May 1;64(5):743-748.
Wang B, Zhou TY, Nie CH, Wan DL, Zheng SS. Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation in liver cancer.Biochem Biophys Res Commun. 2018 May 5;499(2):156-163.
Chen J, Song W, Du Y, Li Z, Xuan Z, Zhao L, Chen J, Zhao Y, Tuo B, Zheng S, Song P. Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation. Biochem Biophys Res Commun. 2018 May 15;499(3):433-440.
Qian YG, Ye Z, Chen HY, Lv Z, Zhang AB, Fan L, Zhou J, Zheng SS, Wang WL. LINC01121 Inhibits Cell Apoptosis While Facilitating Proliferation, Migration, and Invasion Though Negative Regulation of the Camp/PKA Signaling Pathway via GLP1R. Cell Physiol Biochem. 2018 May 24;47(3):1007-1024.
Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, Xie H, Zhou L, Zheng S. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett. 2018 Jun;15(6):9126-9132.
Wang J, Tian Y, Chen H, Li H, Zheng S. Key signaling pathways, genes and transcription factors associated with hepatocellular carcinoma. Mol Med Rep. 2018 Jun;17(6):8153-8160.
Sun J, Zhou G, Zhang Y,Zheng S, Zhou T, Nie C ,Zhu T ,Chen S, Wang B, Yu Z, Wang H, Chen X, Hong L, Chen L Wang W, Zheng S. Comprehensive analysis of common safety profiles and their predictive factors in 520 records of liver cancer patients treated by drug-eluting beads transarterial chemoembolization. Medicine (Baltimore). 2018 Jun;97(26):e11131.
Sun W, He B, Yang B, Hu W, Cheng S, Xiao H, Yang Z, Wen X, Zhou L, Xie H, Shen X, Wu J, Zheng S. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma. Lab Invest. 2018 Jun;98(6):734-744.
Chen J, Zhuo JY, Yang F, Liu ZK, Zhou L, Xie HY, Xu X, Zheng SS. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):220-226.
Geng L, Wang LD, Huang JJ, Shen T, Wang ZY, Lin BY, Ye YF, Zheng SS. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes. Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):204-209.
Zhou GH, Han J, Sun JH, Zhang YL, Zhou TY, Nie CH, Zhu TY, Chen SQ, Wang BQ, Yu ZN1,2, Wang HL, Chen LM, Wang WL, Zheng SS. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients. BMC Cancer. 2018 Jun 8;18(1):644.
京公网安备 11010802027423号